COMP <GO>
PMCB vs CELZ // GROSS PROFIT MARGIN
PharmaCyte Biotech Inc. (NASDAQ) VS. Creative Medical Technology Holdings Inc. (NASDAQ) • 15-METRIC TALLY: PMCB 1
— CELZ 3
■ METRIC PARITY
LAST: $0.33 (-0.78%) • MKT CAP: $3.6M
gross-margins
—
LAST: $0.68 (-5.78%) • MKT CAP: $5.2M
gross-margins
63.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PMCB VS. CELZ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PMCB | CELZ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | 63.40% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -30.20% | -35.00% | +4.80 | PMCB | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -45.50% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 0.20 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | CELZ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 25.9 | 31.7 | -5.80 | CELZ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.6M | $5.2M | -$1.6M | CELZ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PMCB REV | CELZ REV | PMCB GROSS % | CELZ GROSS % | PMCB FCF | CELZ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $6.0K | — | 63.4% | -$5.2M | -$5.9M |
| FY 2024 | $0 | $11.0K | — | 60.0% | -$3.0M | -$5.3M |
| FY 2023 | $0 | $9.0K | — | — | -$2.2M | -$8.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PMCB // BETA —
CELZ // BETA —